New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies

Blood Reviews

Volumn 20, Issue 5, 2006, Pages 267-287

  Leather, Helen L ^a   Wingard, John R ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Hepatology and Nutrition   (United States)

Author keywords

Antifungal; Combination therapy; Diagnostics; Empirical; Galactomannan; Preemptive; Presumptive; Prophylaxis; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; POSACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DRUG FORMULATION; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION RISK; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS;

ALGORITHMS; ANTIFUNGAL AGENTS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES;

EID: 33746876399     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2006.03.001     Document Type: Article

References (123)

1. EORTC. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989;86:668-672.
2. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 (1982) 101-111
3. Kern W., Behre G., Rudolf T., et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia. Results of a prospective randomized phase III trial. Cancer 83 (1998) 291-301
4. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 (1992) 845-851
5. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 171 (1995) 1545-1552
6. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96 (2000) 2055-2061
7. MacMillan M.L., Goodman J.L., DeFor T.E., and Weisdorf D.J. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 112 (2002) 369-379
8. Wolff S.N., Fay J., Stevens D., et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 25 (2000) 853-859
9. Koh L.P., Kurup A., Goh Y.T., Fook-Chong S.M., and Tan P.H. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 71 (2002) 260-267
10. Winston D.J., Chandrasekar P.H., Lazarus H.M., et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multi-center trial. Ann Intern Med 118 (1993) 495-503
11. Vardakas K.Z., Michalopoulos A., and Falagas M.E. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomized-controlled trials. Br J Haem 131 (2005) 22-28
12. Rotstein C., Bow E.J., Laverdiere M., et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 28 (1999) 331-340
13. Perfect J.R., Klotman M.E., Gilbert C.C., Crawford D.D., Rosner G.L., Wright K.A., et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 165 (1992) 891-897
14. Rousey S.R., Russler S., Gottlieb M., and Ash R.C. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 91 (1991) 484-491
15. Karthaus M., Doellmann T., Klimasch T., et al. Intensive intravenous amphotericin B prophylaxis of systemic fungal infections: results of a prospective controlled pilot study in acute leukemia patients. Chemotherapy 46 (2000) 293-302
16. Riley D.K., Pavia A.T., Beatty P.G., Petersen F.B., Spruance J.L., Stokes R., et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J med 76 (1994) 509-514
17. Mattiuzzi G.N., Estey E., Raad I., et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97 (2003) 450-456
18. Tollemar J., Ringden O., Andersson S., Sundberg B., Ljungman P., and Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 12 (1993) 577-582
19. Kelsey S.M., Goldman J.M., McCann S., Newland A.C., Scarffe J.H., Oppenheim B.A., et al. Liposomal amphotericin (Ambisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind, placebo-controlled study. Bone Marrow Transplant 23 (1999) 163-168
20. Brincker H. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. Acta Med Scand 204 (1978) 123-128
21. Wingard J.R., Vaughan W.P., Braine H.G., Merz W.G., and Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 83 (1987) 1103-1110
22. Wiley J.M., Smith N., Leventhal B.G., et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 8 (1990) 280-286
23. Palmblad J., Lonnqvist B., Carlsson B., et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias. J Intern Med 231 (1992) 363-370
24. Benhamou E., Hartmann O., Nogues C., Maraninchi D., Valteau D., and Lemerle J. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant 7 (1991) 127-131
25. Hansen R.M., Reinerio N., Sohnle P.G., Abrams R.A., Ritch P.S., Libnoch J.A., et al. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med 147 (1987) 710-712
26. Estey E., Maksymiuk A., Smith T., et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med 144 (1984) 1562-1568
27. Marr K.A., Crippa F., Leisenring W., Crippa F., Slattery J.T., Corey L., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 1527-1533
28. Winston D.J., Maziarz R.T., Chandrasekar P.H., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138 (2003) 705-713
29. Menichetti D., del Favero A., Martino P., et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 28 (1999) 250-255
30. Morgenstern G.R., Prentice A.G., Prentice H.G., Ropner J.E., Schey S.A., and Warnock D.W. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infection in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haem 105 (1999) 901-911
31. Harousseau J., Dekker A., Stamatoullas-Bastard A., et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematologic malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44 (2000) 1887-1893
32. Huijgens P.C., Simoons-Smit A.M., van Loenen A.C., Prooy E., van Tinteren H., Ossenkppele G.J., et al. Fluconazole versus itraconazole for the prevention of fungal infections in hemato-oncology. J Clin Pathol 52 (1999) 376-380
33. Nucci M., Biasoli I., Akiti T., et al. A double-blind, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30 (2000) 300-305
34. Boogaerts M., Maertens J., van Hood A., et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48 (2001) 97-103
35. th, 2005; Washington DC. Abstract 2111.
36. Van Burik J.H., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
37. Wingard J.R. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 39 Suppl 4 (2004) S176-S180
38. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of the Center for Disease Control and Prevention, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2000;6:659-734.
39. Safdar, van Rhee F., Henslee-Downey J.P., Singhal S., and Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 28 (2001) 873-878
40. Kanda Y., Yamamoto R., Chizuka A., et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: a meta-analysis of 16 randomized, controlled trials. Cancer 89 (2002) 1611-1625
41. Bow E.J., Laverdiere M., Lussier N., Rotstein C., Cheany M.S., and Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials. Cancer 94 (2002) 3230-3246
42. Wingard J.R., Mertz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., and Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325 (1991) 1274-1277
43. Persons D.A., Laughlin M., Tanner D., Perfect J., Gockerman J.P., and Hathorn J.W. Fluconazole and Candida krusei fungemia. N Engl J Med 325 (1991) 1315
44. Wingard J.R., Mertz W.G., Rinaldi M.G., Miller C.B., Karp J.E., and Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 37 (1993) 1847-1849
45. Glasmacher A., Prentice A., Gorschluter M., Engelhart S., Hahn C., Djulbegovic B., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21 (2003) 4615-4626
46. Schwartz S., Behre G., Heinemann V., et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 93 (1999) 3654-3661
47. Behre G.F., Schwartz S., Lenz K., et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 71 (1995) 287-291
48. Drew R.H., Dodds A.E., Benjamin D.K., Davis D., Palmer S.M., and Perfect J.R. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232-237
49. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 357 (2002) 408-415
50. Kullberg B.J., Pappas P., Ruhnke M., et al. Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment of candidemia in non-neutropenic patients. Clin Microbiol Infect 10 Suppl 3 (2004) 41 [Abstract O245]
51. Husain S., Zaldonis D.B., Kwak E.J., and McCurry K.R. Role of voriconazole prophylaxis for the prevention of invasive aspergillosis (IA) at six months in lung transplant recipients. J Heart Lung Transplant 23 (2004) S110 [Abstract 205]
52. Van Well G.T., van Groeningen I., Debets-Ossenkopp Y.J., van Furth A.M., and Zawaan C.M. Zygomycete infection following voriconazole prophylaxis. Lancet Infect Dis 5 (2005) 594
53. Kontoyiannis D.P., Lionakis M.S., Lweis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. Clin Infect Dis 191 (2005) 1350-1360
54. Imhof A., Balajee S.A., Fredericks D.N., Englund J.A., and Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39 (2004) 743-746
55. Marty F.M., Cosimi L.A., and Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350 (2004) 950-952
56. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 39 (2004) 584-587
57. Vigouroux S., Morin O., Moreau P., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 40 (2005) e35-e37
58. Kobayashi K., Kami M., Murashige N., Kishi Y., Fujisaki G., and Mitamura T. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 89 (2004) ECR42
59. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 40 (2005) 770-771
60. Mattner F., Weissbrodt H., and Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infections in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 36 (2004) 312-314
61. Marr K.A., Carter R.A., Crippa F., Wald, and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
62. Kontoyiannis D.P., Wessel V.C., Bodey G.P., and Rolston K.I. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 30 (2002) 851-856
63. th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 - November 2, 2004; Washington DC. Abstract M-666.
64. Bennett J.E., Powers J., Walsh T., et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 36 Suppl 3 (2003) S117-S122
65. Viscoli C., Castagnola E., van Lint M.T., et al. Fluconazole versus amphotericin B as empiric antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicenter, prospective and randomized clinical trial. Eur J Cancer 32A (1996) 814-820
66. Malik I.A., Moid I., Aziz Z., Khan S., and Suleman M. A randomized comparison of fluconazole with amphotericin B as empirical antifungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105 (1998) 478-483
67. Winston D.J., Hathorn J.W., Schuster M.G., Schiller G.J., and Territo M.C. A multicenter, randomized trial of fluconazole versus amphotericin B for empirical antifungal therapy in neutropenic patients with cancer. Am J Med 108 (2000) 282-289
68. Prentice H.G., Hann I.M., Herbrecht R., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98 (1997) 711-718
69. White M.H., Bowden R.A., Sandler E.S., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27 (1998) 296-302
70. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340 (1999) 764-771
71. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Am J Med 135 (2001) 412-422
72. Wingard J.R., White M.H., Anaissie R., Raffalli J., Goodman J., Arrieta A., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31 (2000) 1155-1163
73. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002) 225-234
74. Walsh T.J., Teppler H.A., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
75. Wingard J.R. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39 (2004) S38-S43
76. Maertens J.A., Theunissen K., and Boogaerts M.A. In: Wingard J.R., and Anaissie E.J. (Eds). Fungal Infections in the Immunocompromised Patient (2005), Taylor and Francis, Boca Raton 621-635
77. Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol 43 Suppl 1 (2005) LS147-LS154
78. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computer tomography scans in patients with neutropenia. J Clin Oncol 19 (2001) 253-259
79. Maertens J., Verhaegen J., Lagrou K., van Eldere J., and Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation patients: a prospective validation. Blood 97 (2001) 1604-1610
80. Maertens J., van Eldere J., Verhaegen J., Verbeken E., Verschalkelen J., and Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant patients. J Infect Dis 186 (2002) 1297-1306
81. Sulahian A., Boutboul F., Ribaud P., Leblanc T., Lacroix C., and Derouin F. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91 (2001) 311-318
82. Boutboul F., Alberti C., Leblanc T., Sulahian A., Gluckman E., Derouin F., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 34 (2002) 939-943
83. Rovira M., Jiminez M., De La Bellacasa J.P., et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 77 (2004) 1260-1264
84. Kawazu M., Kanda Y., Nannya Y., et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 → 3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with haematological disorders. J Clin Microbiol 42 (2004) 2733-2741
85. Herbrecht R., Letscher-Bru V., Oprea C., et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 20 (2002) 1898-1906
86. Pinel C., Fricker-Hidalgo H., Lebeau, Garban F., Hamidfar R., Ambroise-Thomas P., et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 41 (2003) 2184-2186
87. Maertens J., Theunissen K., Verbeken E., Lagrou K., Verhaegen J., Boogaerts M., et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126 (2004) 852-860
88. Hebart H., Loffler J., Meisner C., et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 181 (2000) 1713-1719
89. Lass-Florl C., Aigner J., Gunsilius B., et al. Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol 113 (2001) 180-184
90. Hebart H., Loffler J., Reitzke H., et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 111 (2000) 635-640
91. Odabasi Z., Mattiuzzi G., Estey E., et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39 (2004) 199-205
92. Ostrosky-Zeichneer L., Alexander B., Kett D.H., et al. Multicenter clinical evaluation of the (1 → 3) β-D-Glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41 (2005) 654-659
93. Pazos C., Ponton J., and Del Palacio A. Contribution of (1 → 3)-β-D-Glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43 (2005) 299-305
94. Kami M., Fukui T., Ogawa S., et al. Use of real-time OCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 33 (2001) 1504-1512
95. Marr K.A., Balajee S.A., McLaughlin L., Tabouret M., Bentsen C., and Walsh T.J. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. Clin Infect Dis 190 (2004) 641-649
96. Weisser M., Rausch C., Droll A., et al. Galactomannan does not preceded major signs on a pulmonary computerized tomography scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 41 (2005) 1143-1149
97. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (2005) 1242-1250
98. Anaissie E.J., Vartivarian S.E., Abi-Said D., et al. Fluconazole versus amphotericin B in the treatment of hematogenous Candidiasis: a matched cohort study. Am J Med 101 (1996) 170-176
99. Phillips P., Shafran S., Garber G., et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 16 (1997) 337-345
100. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331 (1994) 1325-1330
101. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
102. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
103. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Practice guidelines for the treatment of Candidiasis. Clin Infect Dis 38 (2004) 161-189
104. Bowden R., Chandresekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 15 (2002) 359-366
105. rd, 2004; Boson MA. Abstract 629.
106. Trifilio S., Ortiz R., Pennick G., et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35 (2005) 509-513
107. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M. The influence of inadequate antimicrobial treatment of bloodstream infections on patient's outcomes in the ICU setting. Chest 118 (2000) 146-155
108. Greene R. ECCMID 2003 Abstract.
109. Saag M.S., Graybill R.J., Larsen R.A., Pappas P.G., Perfect J.R., Powderly W.G., et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30 (2000) 710-718
110. Arikan S., Lozano-Chiu M., Paetznick V., and Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46 (2002) 245-247
111. Dannaoui E., Lortholary O., and Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 48 (2004) 970-978
112. Kirkpatrick W.R., Perea S., Coco B.J., and Patterson T.F. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 46 (2002) 2564-2568
113. Manavathu E.K., Alangaden G.J., and Chandrasekar P.H. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 51 (2003) 1423-1425
114. Perea S., Gonzalez G., Fothergill A.W., Kirkpatrick W.R., Rinaldi M.G., and Patterson T.F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 46 (2002) 3039-3041
115. Luque J.C., Clemons K.V., and Stevens D.A. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 47 (2003) 1452-1455
116. MacCallum D.M., Whyte J.A., and Odds F.C. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 49 (2005) 3697-3701
117. Graybill J.R., Bocanegra R., Gonzalez G.M., and Najvar L.K. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 52 (2003) 656-662
118. Chandresaker P.H., Cutright J.L., and Manavathu E.K. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 10 (2004) 925-928
119. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
120. Kontoyiannis D.P., Hachem R., Lewis re, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299
121. Aliff T.B., Maslak P.G., Jurcic J.G., Heaney M.L., Cathcart K.N., Sepkowitz K.A., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97 (2003) 1025-1032
122. Kontoyiannis D.P., Boktour M., Hanna H., Hachem R., and Raad I.I. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 103 (2005) 2334-2337
123. Marr K.A., Boeckh M., Carter R.A., Kim H.Q.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802